AML and HR-MDS have higher levels of CD47 than normal hematopoietic stem cells, contributing to the poor prognosis by enabling the evasion of phagocyte-mediated immune surveillance [58,59]. This evidence concerns the gene CD47 and myelodysplastic syndrome.